{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:52:31Z","timestamp":1793839951780,"version":"4.6.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K12493"],"award-info":[{"award-number":["20K12493"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.resinv.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T08:23:19Z","timestamp":1656577399000},"page":"613-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-6995","authenticated-orcid":false,"given":"Masashi","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-9026","authenticated-orcid":false,"given":"Yasuhiko","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Hachisu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-4579","authenticated-orcid":false,"given":"Noriaki","family":"Sunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-1617","authenticated-orcid":false,"given":"Toshitaka","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-1887","authenticated-orcid":false,"given":"Takeshi","family":"Hisada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2022.05.006_bib1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1378\/chest.126.2.566","article-title":"Mycobacterium avium complex pulmonary disease in patients without HIV infection","volume":"126","author":"Field","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib2","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/AAC.04577-14","article-title":"Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib3","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1164\/rccm.201501-0067OC","article-title":"Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species","volume":"191","author":"Boyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1469-0691.2012.03929.x","article-title":"Genetic relatedness of Mycobacterium avium-intracellulare complex isolates from patients with pulmonary MAC disease and their residential soils","volume":"19","author":"Fujita","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.resinv.2022.05.006_bib5","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1128\/AEM.00930-06","article-title":"Relationships between Mycobacterium isolates from patients with pulmonary mycobacterial infection and potting soils","volume":"72","author":"De Groote","year":"2006","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.resinv.2022.05.006_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/519383","article-title":"The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC","volume":"45","author":"Nishiuchi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib7","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1128\/JCM.00899-13","article-title":"Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM","volume":"51","author":"Thomson","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.resinv.2022.05.006_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3201\/eid1703.101510","article-title":"Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease","volume":"17","author":"Falkinham","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fmed.2017.00027","article-title":"Infection sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium complex","volume":"4","author":"Nishiuchi","year":"2017","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3201\/eid2503.180336","article-title":"Mycobacterium avium in community and household water, suburban philadelphia, Pennsylvania, USA, 2010-2012","volume":"25","author":"Lande","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jiac.2019.10.009","article-title":"A retrospective observational study of antimicrobial treatment for non-tuberculous mycobacteria disease using a nationwide claims database in Japan","volume":"26","author":"Igari","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1513\/AnnalsATS.201304-085OC","article-title":"Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease","volume":"11","author":"Adjemian","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2022.05.006_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0038-1660472","article-title":"Treatment of Mycobacterium avium complex (MAC)","volume":"39","author":"Griffith","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01855-2016","article-title":"Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases","volume":"49","author":"van Ingen","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.05.006_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.05.006_bib18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline: executive summary","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/Azalide therapy for nodular\/bronchiectatic mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jgar.2020.01.004","article-title":"Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: a propensity score analysis","volume":"22","author":"Kwon","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.resinv.2022.05.006_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.resinv.2020.09.010","article-title":"Resumption\/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen","volume":"59","author":"Kobayashi","year":"2021","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2022.05.006_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1086\/515597","article-title":"Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients","volume":"178","author":"Griffith","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/rccm.200509-1531OC","article-title":"Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease","volume":"173","author":"Lam","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2019-000434","article-title":"Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular\/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol","volume":"6","author":"Nakagawa","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2022.05.006_bib26","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1128\/AAC.00648-15","article-title":"Response to switch from intermittent therapy to daily therapy for refractory nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"59","author":"Koh","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/QCO.0b013e3283511a64","article-title":"Therapy of refractory nontuberculous mycobacterial lung disease","volume":"25","author":"Griffith","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib30","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2022.05.006_bib31","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib32","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1136\/bmj.1.5033.1444","article-title":"Toxic effect of streptomycin upon balance and hearing","volume":"1","author":"Cawthorne","year":"1957","journal-title":"Br Med J"},{"issue":"SUPPL","key":"10.1016\/j.resinv.2022.05.006_bib33","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1093\/infdis\/135.Supplement_2.S441","article-title":"A review of results of clinical trials with amikacin","volume":"134","author":"Gooding","year":"1976","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0002-9343(77)90660-X","article-title":"Ototoxicity and nephrotoxicity of amikacin: an overview of phase II and phase III experience in the United States","volume":"62","author":"Lane","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.9.6.956","article-title":"Ototoxicity of amikacin","volume":"9","author":"Black","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib36","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/infdis\/jiaa354","article-title":"Mycobacterium avium complex: addressing gaps in diagnosis and management","volume":"222","author":"Daley","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib37","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/cid\/ciy804","article-title":"Association between duration of aminoglycoside treatment and outcome of cavitary Mycobacterium avium complex lung disease","volume":"68","author":"Kim","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib38","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib39","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.resinv.2022.05.006_bib40","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"How I Do It: managing M. avium complex lung disease with a little help from my friend","volume":"159","author":"Griffith","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.resinv.2022.05.006_bib41","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib42","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","article-title":"Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial","volume":"18","author":"Winthrop","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2022.05.006_bib43","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.8796-21","article-title":"Liposomal amikacin inhalation suspension-induced pneumonitis","author":"Kidogawa","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib44","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1164\/ajrccm.149.3.8118654","article-title":"Oral desensitization to rifampin and ethambutol in mycobacterial disease","volume":"149","author":"Matz","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib45","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2018.12.017","article-title":"Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications","volume":"147","author":"Ban","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.200407-863OC","article-title":"Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease","volume":"172","author":"Griffith","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/WNO.0000000000000445","article-title":"Re-treatment with ethambutol after toxic optic neuropathy","volume":"37","author":"Bouffard","year":"2017","journal-title":"J Neuro Ophthalmol"},{"key":"10.1016\/j.resinv.2022.05.006_bib48","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3346\/jkms.2020.35.e59","article-title":"Treatment outcomes after discontinuation of ethambutol due to adverse events in Mycobacterium avium complex lung disease","volume":"35","author":"Kwon","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.resinv.2022.05.006_bib49","first-page":"AAC0152221","article-title":"Efficacy of fluoroquinolones as substitutes for ethambutol or rifampin in the treatment of Mycobacterium avium complex pulmonary disease according to radiologic types","author":"Lee","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib50","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1749-6632.1966.tb45532.x","article-title":"The ocular toxicity of ethambutol and its relation to dose","volume":"135","author":"Leibold","year":"1966","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.resinv.2022.05.006_bib51","first-page":"91","article-title":"High dose ethambutol; an oral alternate for intermittent chemotherapy","volume":"110","author":"Sbarbaro","year":"1974","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib52","first-page":"699","article-title":"High-dose ethambutol: its role in intermittent chemotherapy. A six-year study","volume":"114","author":"Albert","year":"1976","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01787-19","article-title":"Intermittent treatment with azithromycin and ethambutol for noncavitary Mycobacterium avium complex pulmonary disease","volume":"64","author":"Moon","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib54","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12890-019-0982-8","article-title":"Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib55","doi-asserted-by":"crossref","DOI":"10.21037\/amj-20-66","article-title":"Effective treatment with macrolide and ethambutol for mycobacterium avium complex pulmonary disease","volume":"5","author":"Ito","year":"2020","journal-title":"AME MEDICAL JOURNAL"},{"key":"10.1016\/j.resinv.2022.05.006_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.resinv.2022.05.006_bib57","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/infdis\/171.3.747","article-title":"Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection","volume":"171","author":"Wallace","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jiac.2021.10.003","article-title":"Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection","volume":"28","author":"Iketani","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib60","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1086\/514748","article-title":"A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex","volume":"28","author":"Gordin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib61","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/378807","article-title":"A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome","volume":"37","author":"Benson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2017-000242","article-title":"British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"4","author":"Haworth","year":"2017","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2022.05.006_bib63","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jmii.2017.05.001","article-title":"In\u00a0vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates","volume":"51","author":"Huang","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.resinv.2022.05.006_bib64","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","article-title":"High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria","volume":"35","author":"Shen","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.resinv.2022.05.006_bib65","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In\u00a0vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02349-19","article-title":"Synergistic activity of clofazimine and clarithromycin in an aerosol mouse model of Mycobacterium avium infection","volume":"64","author":"Lanoix","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib67","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.resinv.2022.05.006_bib68","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib69","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib70","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2017.04.175","article-title":"Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection","volume":"152","author":"Martiniano","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib71","article-title":"Outcomes of inhaled amikacin and clofazimine-containing regimens for treatment of refractory Mycobacterium avium complex pulmonary disease","volume":"9","author":"Kim","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.resinv.2022.05.006_bib72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome","volume":"159","author":"Kwak","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib73","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2022.05.006_bib74","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.05.006_bib75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.resinv.2022.05.006_bib76","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2022.05.006_bib77","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.05.006_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01798-16","article-title":"In\u00a0vitro susceptibility testing of bedaquiline against Mycobacterium avium complex","volume":"61","author":"Brown-Elliott","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib79","article-title":"Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections","volume":"49","author":"Vesenbeckh","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.05.006_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00665-19","article-title":"In\u00a0vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates","volume":"63","author":"Kim","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib81","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib82","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/jac\/dku504","article-title":"Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug","volume":"70","author":"Svensson","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib83","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib84","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3201\/eid2703.202359","article-title":"Bedaquiline as treatment for disseminated nontuberculous mycobacteria infection in 2 patients Co-infected with HIV","volume":"27","author":"Gil","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib85","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00118-2019","article-title":"Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease","volume":"54","author":"Zweijpfenning","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.05.006_bib86","doi-asserted-by":"crossref","first-page":"996","DOI":"10.5588\/ijtld.17.0174","article-title":"Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease","volume":"21","author":"Yoon","year":"2017","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib87","series-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes","author":"Woods","year":"2011"},{"key":"10.1016\/j.resinv.2022.05.006_bib88","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2217\/fmb.14.60","article-title":"Drug susceptibility testing of nontuberculous mycobacteria","volume":"9","author":"van Ingen","year":"2014","journal-title":"Future Microbiol"},{"key":"10.1016\/j.resinv.2022.05.006_bib89","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10156-011-0303-5","article-title":"The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease","volume":"18","author":"Fujita","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib90","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12879-016-1384-7","article-title":"Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"16","author":"Kadota","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib91","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1128\/AAC.02281-12","article-title":"Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen","volume":"57","author":"Koh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib92","doi-asserted-by":"crossref","first-page":"ofz108","DOI":"10.1093\/ofid\/ofz108","article-title":"Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease","volume":"6","author":"Asakura","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib93","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01240-2019","article-title":"Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease","volume":"55","author":"Khadawardi","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2022.05.006_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235797","article-title":"Efficacy and safety of fluoroquinolone-containing regimens in treating pulmonary Mycobacterium avium complex disease: a propensity score analysis","volume":"15","author":"Shuto","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2022.05.006_bib95","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1086\/313771","article-title":"Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis","volume":"30","author":"Narita","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib96","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1128\/AAC.42.3.631","article-title":"Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers","volume":"42","author":"Hafner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib97","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/clinids\/23.5.983","article-title":"Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus","volume":"23","author":"Griffith","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib98","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1164\/ajrccm\/141.4_Pt_1.821","article-title":"Rifabutin (ansamycin LM427) for the treatment of pulmonary Mycobacterium avium complex","volume":"141","author":"O'Brien","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00155-17","article-title":"Rifabutin is active against Mycobacterium abscessus complex","volume":"61","author":"Aziz","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib100","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.chest.2020.10.031","article-title":"Managing Mycobacterium avium complex lung disease with a little help from my friend","volume":"159","author":"Griffith","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2022.05.006_bib101","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/clinids\/21.3.594","article-title":"Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease","volume":"21","author":"Griffith","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib102","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0924-8579(03)00048-7","article-title":"In\u00a0vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria","volume":"21","author":"Rodriguez Diaz","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.resinv.2022.05.006_bib103","first-page":"411","article-title":"Activities of Linezolid against nontuberculous mycobacteria","volume":"30","author":"Cavusoglu","year":"2007","journal-title":"New Microbiol"},{"key":"10.1016\/j.resinv.2022.05.006_bib104","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/jac\/dkx304","article-title":"Linezolid as treatment for pulmonary Mycobacterium avium disease","volume":"72","author":"Deshpande","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib105","first-page":"1125","article-title":"Linezolid in the treatment of disseminated nontuberculous mycobacterial infection in anti-interferon-gamma autoantibody-positive patients","volume":"45","author":"Chetchotisakd","year":"2014","journal-title":"Southeast Asian J Trop Med Publ Health"},{"key":"10.1016\/j.resinv.2022.05.006_bib106","first-page":"606","article-title":"Linezolid for the treatment of patients with [corrected] mycobacterial infections [corrected] a systematic review","volume":"11","author":"Ntziora","year":"2007","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.resinv.2022.05.006_bib107","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In\u00a0vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.resinv.2022.05.006_bib108","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jac\/dkz511","article-title":"Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?","volume":"75","author":"Ruth","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib109","first-page":"65","article-title":"The benzimidazole SPR719 shows promising concentration-dependent activity and synergy against nontuberculous mycobacteria","author":"Pennings","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.resinv.2022.05.006_bib110","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1183\/13993003.01420-2016","article-title":"Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?","volume":"48","author":"Krieger","year":"2016","journal-title":"Eur Respir J"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534522000624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534522000624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:32:04Z","timestamp":1761949924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534522000624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2212534522000624"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2022.05.006","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}